Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

August 8, 2023 06:52 AM EDTUpdated 11:29 AM

Updated: Novo Nordisk's semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Katherine Lewin

News Reporter

Novo Nordisk’s semaglutide injection reduced major adverse cardiovascular events by 20% in obese or overweight patients without diabetes, further bolstering the case for more widespread …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Novo Nordisk's semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Updated: Novo Nordisk's semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.